Market open
Pulmonx/$LUNG
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pulmonx
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Ticker
$LUNG
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
279
Website
Pulmonx Metrics
BasicAdvanced
$291M
Market cap
-
P/E ratio
-$1.47
EPS
0.64
Beta
-
Dividend rate
Price and volume
Market cap
$291M
Beta
0.64
52-week high
$14.84
52-week low
$5.46
Average daily volume
213K
Financial strength
Current ratio
7.701
Quick ratio
6.527
Long term debt to equity
58.607
Total debt to equity
59.419
Interest coverage (TTM)
-16.30%
Management effectiveness
Return on assets (TTM)
-20.65%
Return on equity (TTM)
-51.99%
Valuation
Price to revenue (TTM)
3.602
Price to book
3.08
Price to tangible book (TTM)
3.16
Price to free cash flow (TTM)
-8.21
Growth
Revenue change (TTM)
22.34%
Earnings per share change (TTM)
-9.35%
3-year revenue growth (CAGR)
21.20%
3-year earnings per share growth (CAGR)
5.12%
What the Analysts think about Pulmonx
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pulmonx stock.
Pulmonx Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pulmonx Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pulmonx News
AllArticlesVideos
Pulmonx to Present at the Stifel 2024 Healthcare Conference
GlobeNewsWire·3 days ago
Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024
GlobeNewsWire·3 weeks ago
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pulmonx stock?
Pulmonx (LUNG) has a market cap of $291M as of November 08, 2024.
What is the P/E ratio for Pulmonx stock?
The price to earnings (P/E) ratio for Pulmonx (LUNG) stock is 0 as of November 08, 2024.
Does Pulmonx stock pay dividends?
No, Pulmonx (LUNG) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Pulmonx dividend payment date?
Pulmonx (LUNG) stock does not pay dividends to its shareholders.
What is the beta indicator for Pulmonx?
Pulmonx (LUNG) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.